- Home
- EU vs HUMA Comparison
EU vs HUMA Comparison
Compare EU & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EU | HUMA |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 165.7M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EU | HUMA |
|---|---|---|
| Price | $0.59 | $0.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $2.83 | $1.64 |
| AVG Volume (30 Days) | 2.8M | ★ 5.6M |
| Earning Date | 08-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.76 | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,155,000.00 | $2,038,000.00 |
| Revenue This Year | $59.92 | $89.63 |
| Revenue Next Year | $23.87 | $534.28 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.62 | $0.34 |
| 52 Week High | $3.68 | $1.53 |
Technical Indicators
Market Signals| Indicator | EU | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 32.16 | 62.19 |
| Support Level | N/A | $0.54 |
| Resistance Level | $1.47 | $0.61 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 2.65 | 75.09 |
Price Performance
Historical ComparisonAbout EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.